This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

72/100

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. Objectives To assess the clinical effects of galantamine in patients with mild cognitive impairment (MCI), probable or possible Alzheimer's disease (AD), and potential moderators of effect. Search strategy The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, last updated on 25 April 2005 using the terms galanthamin*, galantamin* and Reminyl.

What this study adds

Evidence grade: High

This is a pooled review of 6,805 participants. This is a Cochrane review protocol assessing the clinical effects of galantamine, an acetylcholinesterase inhibitor, in people with mild cognitive impairment and Alzheimer's disease. The text provided does not report any results, so no conclusion about treating, curing, or preventing Alzheimer's disease can be drawn from it.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Loy, C., & Schneider, L. (2006). Galantamine for Alzheimer's disease and mild cognitive impairment. The Cochrane database of systematic reviews. https://doi.org/10.1002/14651858.cd001747.pub3

Vancouver

Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. The Cochrane database of systematic reviews. 2006. doi:10.1002/14651858.cd001747.pub3. PMID: 16437436.

BibTeX

@article{loy2006-16437436,
  author  = {Loy, C. and Schneider, L.},
  title   = {{Galantamine for Alzheimer's disease and mild cognitive impairment}},
  journal = {The Cochrane database of systematic reviews},
  year    = {2006},
  doi     = {10.1002/14651858.cd001747.pub3},
  pmid    = {16437436},
  url     = {https://doi.org/10.1002/14651858.cd001747.pub3}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: this is a pooled review. It combines earlier studies, so it is only as good as the studies it pools. Check how many were included, whether they were similar enough to combine, and whether the authors report inconsistency between them.
Size: the record lists 6,805 participants. Ask whether that is enough for the question, and who they were.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded high. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. High means the abstract mentions a randomized design, a meta-analysis or a systematic review. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Objectives To assess the clinical effects of galantamine in patients with mild cognitive impairment (MCI), probable or possible Alzheimer's disease (AD), and potential moderators of effect.
Search strategy The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, last updated on 25 April 2005 using the terms galanthamin*, galantamin* and Reminyl.
Published reviews were inspected for further sources.
Additional information was collected from unpublished clinical research reports for galantamine obtained from Janssen and from http://www.clinicalstudyresults.org/.

Why it matters

This is a Cochrane review protocol assessing the clinical effects of galantamine, an acetylcholinesterase inhibitor, in people with mild cognitive impairment and Alzheimer's disease. The text provided does not report any results, so no conclusion about treating, curing, or preventing Alzheimer's disease can be drawn from it.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Participants6,805
Evidence strengthHigh

How this study scored 72/100

Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (The Cochrane database of systematic reviews)
Journal's citation record	3 / 4	Cochrane Database of Systematic Reviews: journal h-index 468 (OpenAlex, 2026-10-29)
Study design	12 / 12	A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”)
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2006 — older than 20 years, still counted
Sample size	3 / 4	6,805 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	A review of other studies — randomization is not credited here
Times cited	6 / 7	Cited 322 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	14.6 citations a year over 22 year(s) since 2006
Impact for its field and year	4 / 6	Cited 13.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 18 other studies in this library
Still being cited	2 / 4	Cited 32 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Lon S. S. Schneider: h-index 87 (OpenAlex, whole career)
Institution's track record	2 / 3	University of Southern California: institution h-index 1,521 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 16437436)
Free to read	0 / 2	Behind a paywall — scores zero
Total	72 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

18 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

Where this led: Galantamine on the treatments page — its current status, approval date, side-effect rate and list price, kept up to date.

See all studies in Treatments →